

(1390 REV. 5-93) US DEPT. OF COMMERCE PATENT & TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER
10797

**TRANSMITTAL LETTER TO THE
UNITED STATES
DESIGNATED/ELECTED OFFICE
(DO/EO/US) CONCERNING A FILING
UNDER 35 U.S.C. 371**

U.S. APPLICATION NO.
(if known, sec 37 C.F.R. 1.5)
09/701,243

JH 11

INTERNATIONAL APPLICATION NO.
PCT/FR99/01247

INTERNATIONAL FILING DATE
May 27, 1999

PRIORITY DATE CLAIMED
May 27, 1998

TITLE OF INVENTION
METHOD FOR AMPLIFYING AT LEAST ONE SPECIFIC NUCLEOTIDE SEQUENCE, AND PRIMERS USED

APPLICANTS FOR DO/EO/US
Bruno MOUGIN et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☒ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ Entitlement to small entity status is hereby asserted.
17. ☒ Other items or information: Copy of Notification of Defective Response and Sequence Listing (paper and computer-readable copies).

U.S. APPLICATION NO. (if known, see C.F.R. 1.5) 09/701,243	INTERNATIONAL APPLICATION NO. PCT/FR99/01247	ATTORNEY'S DOCKET NUMBER 15-076
---	---	------------------------------------

17. <input type="checkbox"/> The following fees are submitted: Basic National fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO\$890.00 International preliminary examination fee paid to USPTO (37 CFR1.482)\$710.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$740.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$1,040.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$ 100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =	CALCULATIONS	PTO USE ONLY																
ENTER APPROPRIATE BASIC FEE AMOUNT =	\$																	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$																	
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:20%;">Claims</th> <th style="width:20%;">Number Filed</th> <th style="width:20%;">Number Extra</th> <th style="width:20%;">Rate</th> </tr> <tr> <td>Total Claims</td> <td style="text-align: center;">- 20 =</td> <td></td> <td>X \$ 18.00</td> </tr> <tr> <td>Independent Claims</td> <td style="text-align: center;">- 3 =</td> <td></td> <td>X \$ 84.00</td> </tr> <tr> <td colspan="2">Multiple dependent claim(s)(if applicable)</td> <td></td> <td>+ \$280.00</td> </tr> </table>	Claims	Number Filed	Number Extra	Rate	Total Claims	- 20 =		X \$ 18.00	Independent Claims	- 3 =		X \$ 84.00	Multiple dependent claim(s)(if applicable)			+ \$280.00		
Claims	Number Filed	Number Extra	Rate															
Total Claims	- 20 =		X \$ 18.00															
Independent Claims	- 3 =		X \$ 84.00															
Multiple dependent claim(s)(if applicable)			+ \$280.00															
TOTAL OF ABOVE CALCULATIONS =	\$																	
Reduction by 1/2 for filing by small entity, if applicable.	-	\$																
SUBTOTAL =	\$																	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 month from the earliest claimed priority date (37 CFR 1.492(f)).	+	\$																
TOTAL NATIONAL FEE =	\$																	
	Amount to be refunded	\$																
	Charged	\$																

a. <input type="checkbox"/> Check No. _____ in the amount of \$_____ to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. <u>15-0461</u> . A duplicate copy of this sheet is enclosed.	<div style="text-align: right;"> NAME: William P. Berridge REGISTRATION NUMBER: 30,024 NAME: Philip A. Caramanica, Jr. REGISTRATION NUMBER: 51,528 </div>
---	---

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status

SEND ALL CORRESPONDENCE TO:
 OLIFF & BERRIDGE, PLC
 P.O. Box 19928
 Alexandria, Virginia 22320

Date: December 18, 2002




UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/701,243	Bruno Mougin	107976

Oliff & Berridge
 PO Box 19928
 Alexandria, VA 22320



INTERNATIONAL APPLICATION NO.	
PCT/FR99/01247	
I.A. FILING DATE	PRIORITY DATE
05/27/1999	03/27/1998

CONFIRMATION NO. 7333
 371 FORMALITIES LETTER



OC000000009105456

DUE DATE

DEC 18 2002

Date Mailed: 11/18/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Preliminary Amendments
- Small Entity Statement

DOCKETED
 By MPX on 11/22 2002
 and
 By GXM on 11/22 2002
Oliff & Berridge

Applicant's response filed 12/28/2000 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 10/01/2001 have not been completed.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

- **APPLICANT MUST PROVIDE:**

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)


*A copy of this notice **MUST** be returned with the response.*

SHELBY J VIGIL

Telephone: (703) 305-3653

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/701,243	PCT/FR99/01247	107976



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/701,243
Source: OLPE
Date Processed by STIC: 8/5/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebs/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



OIPE

RAW SEQUENCE LISTING

DATE: 08/05/2002

PATENT APPLICATION: US/09/701,243,

TIME: 11:43:13

Input Set : A:\EP.txt

Output Set: N:\CRF4\08052002\I701243.raw

3 <110> APPLICANT: MOUGIN, Bruno
 4 LAAYOUN, Ali
 6 <120> TITLE OF INVENTION: METHOD FOR AMPLIFYING AT LEAST ONE SPECIFIC NUCLEOTIDE
 SEQUENCE, AND
 7 PRIMERS USED
 9 <130> FILE REFERENCE: 107976
 11 <140> CURRENT APPLICATION NUMBER: US 09/701,243
 12 <141> CURRENT FILING DATE: 2000-12-28
 14 <150> PRIOR APPLICATION NUMBER: PCT/FR99/01247
 15 <151> PRIOR FILING DATE: 1999-05-27
 17 <150> PRIOR APPLICATION NUMBER: FR 98/06866
 18 <151> PRIOR FILING DATE: 1998-05-27
 20 <160> NUMBER OF SEQ ID NOS: 29
 22 <170> SOFTWARE: PatentIn version 3.1
 24 <210> SEQ ID NO: 1
 25 <211> LENGTH: 23
 26 <212> TYPE: DNA
 27 <213> ORGANISM: artificial sequence
 29 <220> FEATURE:
 30 <223> OTHER INFORMATION: Blocking primer
 32 <400> SEQUENCE: 1
 33 atccttcgtg tccccacagc acg 23
 36 <210> SEQ ID NO: 2
 37 <211> LENGTH: 19
 38 <212> TYPE: DNA
 39 <213> ORGANISM: artificial sequence
 41 <220> FEATURE:
 42 <223> OTHER INFORMATION: Blocking primer
 44 <400> SEQUENCE: 2 19
 45 tcgccgctgc actgtgaag
 48 <210> SEQ ID NO: 3
 49 <211> LENGTH: 24
 50 <212> TYPE: DNA
 51 <213> ORGANISM: artificial sequence
 53 <220> FEATURE:
 54 <223> OTHER INFORMATION: Blocking primer
 56 <220> FEATURE:
 -> 57 <221> NAME/KEY: particular characteristic
 58 <222> LOCATION: (24)..(24)
 59 <223> OTHER INFORMATION: modification by the C6-NH2 group
 62 <400> SEQUENCE: 3
 63 cccccagca cgtttcttgg agct 24
 66 <210> SEQ ID NO: 4
 67 <211> LENGTH: 24

Does Not Comply
Corrected Diskette Needed

pa 1-5

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/701,243

DATE: 05/2002
TIME: 11:43:13

Input Set : A:\EP.txt
Output Set: N:\CRF4\08052002\I701243.raw

68 <212> TYPE: DNA
69 <213> ORGANISM: artificial sequence
71 <220> FEATURE:
72 <223> OTHER INFORMATION: Blocking primer
74 <220> FEATURE:
-> 75 <221> NAME/KEY: particular characteristic
76 <222> LOCATION: (1)..(1)
77 <223> OTHER INFORMATION: modification by the acridine group
-> 80 <220> FEATURE:
-> 81 <221> NAME/KEY: particular characteristic
82 <222> LOCATION: (24)..(24)
83 <223> OTHER INFORMATION: modification by H
86 <400> SEQUENCE: 4
87 cccccagca cgtttcttgg agct
90 <210> SEQ ID NO: 5
91 <211> LENGTH: 26
92 <212> TYPE: DNA
93 <213> ORGANISM: artificial sequence
95 <220> FEATURE:
96 <223> OTHER INFORMATION: Blocking primer
98 <220> FEATURE:
-> 99 <221> NAME/KEY: particular characteristic
100 <222> LOCATION: (24)..(24)
101 <223> OTHER INFORMATION: G means inosine (1)
104 <220> FEATURE:
-> 105 <221> NAME/KEY: particular characteristic
106 <222> LOCATION: (26)..(26)
107 <223> OTHER INFORMATION: modification by the C6-NH2 group
110 <400> SEQUENCE: 5
111 cccacagcac gtttcttggc gcaggc
114 <210> SEQ ID NO: 6
115 <211> LENGTH: 21
116 <212> TYPE: DNA
117 <213> ORGANISM: artificial sequence
119 <220> FEATURE:
120 <223> OTHER INFORMATION: Blocking primer
122 <400> SEQUENCE: 6
123 cccagcacgt ttcttggagc t
126 <210> SEQ ID NO: 7
127 <211> LENGTH: 24
128 <212> TYPE: DNA
129 <213> ORGANISM: artificial sequence
131 <220> FEATURE:
132 <223> OTHER INFORMATION: Blocking primer
134 <400> SEQUENCE: 7
135 cccccagca cgtttcttgg agct
138 <210> SEQ ID NO: 8
139 <211> LENGTH: 24
140 <212> TYPE: DNA

24

26

21

24

**g can only represent itself (guanine)
nothing else. Use 'n' instead,
and explain in
<2207-2223>
26 section*

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/701,243

DATE: 05/2002
TIME: 11:43:13

Input Set : A:\EP.txt
Output Set: N:\CRF4\08052002\I701243.raw

141 <213> ORGANISM: artificial sequence
143 <220> FEATURE:
144 <223> OTHER INFORMATION: Blocking primer
146 <220> FEATURE:
-> 147 <221> NAME/KEY: particular characteristic
148 <222> LOCATION: (23)..(23)
149 <223> OTHER INFORMATION: G means inosine (i) *same error*
152 <400> SEQUENCE: 8
153 cccccagca cgtttcttgg aggt 24
156 <210> SEQ ID NO: 9
157 <211> LENGTH: 24
158 <212> TYPE: DNA
159 <213> ORGANISM: artificial sequence
161 <220> FEATURE:
162 <223> OTHER INFORMATION: Blocking primer
164 <220> FEATURE:
-> 165 <221> NAME/KEY: particular characteristic
166 <222> LOCATION: (22)..(22)
167 <223> OTHER INFORMATION: G means inosine (i)
170 <220> FEATURE:
-> 171 <221> NAME/KEY: particular characteristic *same error*
172 <222> LOCATION: (23)..(23)
173 <223> OTHER INFORMATION: G means inosine (i)
176 <400> SEQUENCE: 9
177 catttctca atgggacgga ggtga 24
180 <210> SEQ ID NO: 10
181 <211> LENGTH: 26
182 <212> TYPE: DNA
183 <213> ORGANISM: artificial sequence
185 <220> FEATURE:
186 <223> OTHER INFORMATION: Blocking primer
188 <220> FEATURE:
-> 189 <221> NAME/KEY: particular characteristic
190 <222> LOCATION: (24)..(24)
191 <223> OTHER INFORMATION: G means inosine (i) *same*
194 <400> SEQUENCE: 10
195 cccccagcac gtttcttgga gcaggc 26
198 <210> SEQ ID NO: 11
199 <211> LENGTH: 26
200 <212> TYPE: DNA
201 <213> ORGANISM: artificial sequence
203 <220> FEATURE:
204 <223> OTHER INFORMATION: Blocking primer
206 <220> FEATURE:
-> 207 <221> NAME/KEY: particular characteristic
208 <222> LOCATION: (24)..(24)
209 <223> OTHER INFORMATION: G means inosine (i) *same*
212 <400> SEQUENCE: 11
213 cccacagcac gtttcttgga gcaggc 26

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/701,243

DATE: 05/2002
TIME: 11:43:13

Input Set : A:\EP.txt
Output Set: N:\CRF4\08052002\I701243.raw

216 <210> SEQ ID NO: 12
217 <211> LENGTH: 19
218 <212> TYPE: DNA
219 <213> ORGANISM: artificial sequence
221 <220> FEATURE:
222 <223> OTHER INFORMATION: Blocking primer
224 <400> SEQUENCE: 12
225 cacgtttctt gcagcagga 19
228 <210> SEQ ID NO: 13
229 <211> LENGTH: 22
230 <212> TYPE: DNA
231 <213> ORGANISM: artificial sequence
233 <220> FEATURE:
234 <223> OTHER INFORMATION: Blocking primer
236 <400> SEQUENCE: 13
237 cagcacgttt cttgcagcag ga 22
240 <210> SEQ ID NO: 14
241 <211> LENGTH: 19
242 <212> TYPE: DNA
243 <213> ORGANISM: artificial sequence
245 <220> FEATURE:
246 <223> OTHER INFORMATION: Blocking primer
248 <220> FEATURE:
-> 249 <221> NAME/KEY: particular characteristic
250 <222> LOCATION: (3)..(3)
251 <223> OTHER INFORMATION: G means inosine (i) same evor
254 <400> SEQUENCE: 14
255 caggtttctt gcagcagga 19
258 <210> SEQ ID NO: 15
259 <211> LENGTH: 22
260 <212> TYPE: DNA
261 <213> ORGANISM: artificial sequence
263 <220> FEATURE:
264 <223> OTHER INFORMATION: Blocking primer
266 <220> FEATURE:
-> 267 <221> NAME/KEY: particular characteristic
268 <222> LOCATION: (6)..(6)
269 <223> OTHER INFORMATION: G means inosine (i) same
272 <400> SEQUENCE: 15
273 cagcacgttt cttgcagcag ga 22
276 <210> SEQ ID NO: 16
277 <211> LENGTH: 26
278 <212> TYPE: DNA
279 <213> ORGANISM: artificial sequence
281 <220> FEATURE:
282 <223> OTHER INFORMATION: Blocking primer
284 <220> FEATURE:
-> 285 <221> NAME/KEY: particular characteristic
286 <222> LOCATION: (10)..(10)

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/701,243

DATE: 5/2002
TIME: 11:43:13

Input Set : A:\EP.txt
Output Set: N:\CRF4\08052002\I701243.raw

287 <223> OTHER INFORMATION: G means inosine (1) *same*
290 <400> SEQUENCE: 16
291 cccccagca gtttcttgca gcagga
294 <210> SEQ ID NO: 17
295 <211> LENGTH: 26
296 <212> TYPE: DNA
297 <213> ORGANISM: artificial sequence
299 <220> FEATURE:
300 <223> OTHER INFORMATION: Blocking primer
302 <220> FEATURE:
> 303 <221> NAME/KEY: particular characteristic
304 <222> LOCATION: (10)..(10)
305 <223> OTHER INFORMATION: G means inosine (1) *same*
308 <400> SEQUENCE: 17
309 cccacagcag gtttcttgca gcagga
312 <210> SEQ ID NO: 18
313 <211> LENGTH: 26
314 <212> TYPE: DNA
315 <213> ORGANISM: artificial sequence
317 <220> FEATURE:
318 <223> OTHER INFORMATION: Blocking primer
320 <220> FEATURE:
> 321 <221> NAME/KEY: particular characteristic
322 <222> LOCATION: (10)..(10)
323 <223> OTHER INFORMATION: G means inosine (1) *same*
326 <220> FEATURE:
> 327 <221> NAME/KEY: particular characteristic
328 <222> LOCATION: (25)..(25)
329 <223> OTHER INFORMATION: G means inosine (1)
332 <400> SEQUENCE: 18
333 cccacagcag gtttcttgca gcagga
336 <210> SEQ ID NO: 19
337 <211> LENGTH: 26
338 <212> TYPE: DNA
339 <213> ORGANISM: artificial sequence
341 <220> FEATURE:
342 <223> OTHER INFORMATION: Blocking primer
344 <220> FEATURE:
> 345 <221> NAME/KEY: particular characteristic
346 <222> LOCATION: (10)..(10)
347 <223> OTHER INFORMATION: G means inosine (1) *same*
350 <220> FEATURE:
> 351 <221> NAME/KEY: particular characteristic
352 <222> LOCATION: (25)..(25)
353 <223> OTHER INFORMATION: G means inosine (1)
356 <400> SEQUENCE: 19
357 cccccagcag gtttcttgca gcagga
360 <210> SEQ ID NO: 20
361 <211> LENGTH: 33

26

26

26

*Please correct this error
in subsequent sequences,*

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/701,243

DATE: 5/2002
TIME: 11:43:14

Input Set : A:\EP.txt

Output Set: N:\CRF4\08052002\I701243.raw

7 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3
5 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4
1 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:4
9 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
05 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
47 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:8
65 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:9
71 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:9
89 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:10
07 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:11
49 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:14
67 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:15
85 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:16
03 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:17
21 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:18
27 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:18
45 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:19
51 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:19